重症监护中的双重照护:危重孕产妇的药物治疗考量
本文综述了危重孕产妇在ICU中的药物治疗考量。妊娠期生理改变与危重症状态叠加,可预测地影响药物吸收、分布、代谢和排泄,且药物与胎盘屏障的相互作用需纳入选择决策。文章围绕生理改变、药物风险分类、支持治疗、脓毒症、心源性休克、急性呼吸窘迫综合征和静脉血栓栓塞等主题展开讨论。
要点
- 妊娠期生理改变(如胃排空延迟、血容量增加、肾小球滤过率升高、心输出量增加)直接影响ICU常用药物的药代动力学。
- 选择药物时需考虑其与胎盘屏障的相互作用,并权衡对母胎的风险与获益。
- 产科危重症入住ICU逐年增加,理解妊娠与危重症的交互作用对优化母胎结局至关重要。
核心结论
- 危重孕产妇的药物治疗需同时兼顾母体与胎儿结局,理解妊娠生理改变与危重症的叠加效应是优化用药选择的关键。
研究设计与样本
- 本文为综述,围绕危重孕产妇ICU药物治疗的多个主题进行汇总讨论。
主要发现
- 妊娠可预测地引起胃排空延迟、血容量和血浆容量增加、肾小球滤过率升高及心输出量增加,从而改变ICU常用药物的药代动力学。
- 妊娠合并危重症时,药物吸收、分布、代谢和排泄的变化难以准确预测。
- 药物代谢及与胎盘屏障的相互作用存在诸多细节,选择用药时需权衡母胎风险与获益。
- 近年来产科危重症入住ICU增多,尤其在冠状病毒流行波期间。
临床怎么用
- ICU临床药师应结合孕周和孕期评估妊娠相关生理改变对目标药物药代动力学的影响。
- 选择药物时需评估其与胎盘屏障的相互作用,并权衡对母体和胎儿的风险与获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Safe and thoughtful medication management of pregnant patients requiring intensive care unit (ICU) level of care is key to optimizing outcomes for both mother and fetus. Pregnancy induces physiologic alterations that closely mirror the changes expected in a critically ill patient. These changes can be predictable depending on the gestational age and trimester and will directly impact the pharmacokinetic profile of medications commonly used in the ICU; examples include decreased gastric emptying, increased blood and plasma volume, increased glomerular filtration, and increased cardiac output. When pregnant patients require ICU care, the resulting impact on drug absorption, distribution, metabolism, and elimination can be difficult to predict. In addition, there are many nuances of medication metabolism and interface with the placental barrier that should be considered when selecting pharmacotherapy for the pregnant patient. Critical care clinicians need to be aware of medication interactions with the placenta and weigh the risk versus benefit profile of medication use in this patient population. Obstetric critical care admissions have increased over the years, especially during the coronavirus waves. Therefore, understanding the interplay between pregnancy and critical illness to optimize pharmacotherapy selection is crucial to improving health outcomes of mother and fetus. This review highlights pharmacotherapy considerations in the pregnant ICU patient for the following topics: physiologic alterations, categorizing medication risk, supportive care, sepsis, cardiogenic shock, acute respiratory distress syndrome, and venous thromboembolism.
引用
- Heavner MS, Erdman G, Barlow B, et al. Caring for two in the ICU: Pharmacotherapy in the critically ill pregnant patient. Pharmacotherapy. 2023. PMID: 36938691. doi:10.1002/phar.2795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。